VA
ORKA

VR Adviser’s Oruka Therapeutics ORKA Stock Holding History

VR Adviser’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$395M Hold
4,148,428
– – 11.97% 2
2026
Q1 		$203M Hold
4,148,428
– – 7.6% 3
2025
Q4 		$126M Hold
4,148,428
– – 6.21% 2
2025
Q3 		$79.8M Hold
4,148,428
– – 4.49% 7
2025
Q2 		$46.5M Hold
4,148,428
– – 3.48% 8
2025
Q1 		$42.6M Buy
4,148,428
+862,808
+26% +$10.8M 3.62% 9
2024
Q4 		$63.7M Buy
3,285,620
+200,000
+6% +$4.88M 4.37% 6
2024
Q3 		$75.6M Buy
3,085,620
+3,013,422
+4,174% +$105M 3.96% 8
2024
Q2 		$3.32M Buy
+72,198
New +$2.88M 0.21% 34

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

VR Adviser's ORKA Position: Q2 2026 in Review

VR Adviser held its Oruka Therapeutics (ORKA) position steady in Q2 2026 at 4,148,428 shares worth $395M. The position accounts for 11.97% of the portfolio, ranked #2.

VR Adviser first reported a position in ORKA in Q2 2024 and has held it in 9 quarters since. 256 funds tracked by Wall St. Rank hold ORKA as of Q2 2026.

  • VR Adviser held 4,148,428 shares of Oruka Therapeutics worth $395M as of Q2 2026.
  • VR Adviser left its Oruka Therapeutics share count unchanged in Q2 2026.
  • Oruka Therapeutics made up 11.97% of VR Adviser's portfolio in Q2 2026, its #2 holding.
  • VR Adviser first reported a position in Oruka Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • 256 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2026.

Based on VR Adviser's 13F filing for Q2 2026, filed 14 Aug 2026.